Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT05702476
Recruiting Observational

Marfan Syndrome (MFS) and Facial Dysmorphism: Non-invasive 3D Assessment

NCT05702476 · tracked via the Priya Life Science Italy tracker
Sponsor
IRCCS Policlinico S. Donato
Phase
Observational
Started
2023-01-09
Last updated
2025-01-13

Condition(s) studied

Rare DiseasesMarfan Syndrome

Study summary

The goal of this study observational prospective study is to define the facial morphological features associated with Marfan syndrome (MFS). The main qustion it aims to answer are:

1. To describe the facial morphological features associated with MFS and their evolution over time;
2. To study the association between facial morphology and the features of reference for the diagnosis of MFS.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * White european ethnicity; * Signed informed consent; Exclusion Criteria: * Previous relevant traumas affecting the craniofacial district or maxillofacial surgery; * Presence of beard and mustache; * Pregnancy

Primary outcome measure(s)

  • Disease Progression — 18 months
    Prospective evaluation focused in the craniofacial area in MFS patients

Trial sites (1)

FacilityCityRegionStatus
IRCCS Policlinico San Donato San Donato Milanese Lombardy Recruiting

More IRCCS Policlinico S. Donato trials in Italy

Novel Risk Prediction Approaches for the Primary Prevention of Cardiovascular Diseases in Italy: the CVRISK-IT Trial (CVRISK-IT) Recruiting
Multivariate Approach to the Numerical Assessment of Cortical - Autonomic - VAscular Dynamic Interplay Recruiting
Heart Failure and Aortic Stenosis Transcriptome Recruiting
RNA as Prognostic Biomarkers in Patients With Acute Coronary Syndrome Recruiting
OUTcomes Evaluation of Current Therapeutic STrategies for Severe Aortic Valve steNosis anD the agING Population in ITALY Recruiting

Other trials for the same condition

Genomic Profiling of Genetic and Rare Diseases Recruiting
Marfan Syndrome and Quality of Life of Pediatric Patients Active, not recruiting
Aortic Stiffness in Patients With Genetic Aortopathies Recruiting
Transcriptomic Study of Adult Population With Marfan Syndrome Active, not recruiting
PREcision Diagnostics in Rare genetIC Diseases and Tumors - Long Read Sequencing Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05702476 on ClinicalTrials.gov ↗ ← All trials in Italy